

Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass (KeyMarker)

 consortiapedia.fastercures.org/consortia/keymarker/

Research Areas



Biomarker Research

Imaging

At a Glance

- Status: **Completed Consortium**
- Year Launched: **2011**
- Initiating Organization: **IBA Group**
- Initiator Type: **Industry**
- Location: **Europe**

Abstract

Mission

The goal of KeyMarker is to identify molecules that can be used as radiotracers for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging and potential quantification of the pancreatic beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease follow-up, and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform as well as the toxicology, bio-distribution, and labeling expertise dedicated to the project form the basis for a standard process for further diabetes imaging tracer evaluation.

Financing

This was a three-year project with a total budget of €2.7 million.



Links/Social Media Feed

Other website <http://biowin.org/Biowin/Keymarker.pdf>

Points of Contact

Richard Zimmermann (project coordinator)
email: richard.zimmermann@iba-group.com

Sponsors & Partners

Eurogenetic

FUNDP

IBA

Trasis

UCL

ULB

ULg

Updated: **04/15/2016**